| 蒋 莎,陈畅乾,卢 娟,陈惠惠,康 旻.卵巢癌组织lncRNA HCG18、miR-152-3p表达与临床病理特征及预后的关系研究[J].,2024,(17):3246-3250 |
| 卵巢癌组织lncRNA HCG18、miR-152-3p表达与临床病理特征及预后的关系研究 |
| Study on the Relationship between the Expression of lncRNA HCG18 and miR-152-3p in Ovarian Cancer Tissues and Clinicopathological Features and Prognosis |
| 投稿时间：2024-03-18 修订日期：2024-04-15 |
| DOI：10.13241/j.cnki.pmb.2024.17.009 |
| 中文关键词: 卵巢癌 lncRNA HCG18 miR-152-3p 病理特征 预后 |
| 英文关键词: Ovarian cancer lncRNA HCG18 miR-152-3p Pathological features Prognosis |
| 基金项目:珠海市社会发展领域科技计划项目（2320000040000287）；珠海市社会发展领域科技计划项目（22200040000198）；广东省自然科学基金面上项目（2023A1515010515） |
|
| 摘要点击次数: 146 |
| 全文下载次数: 72 |
| 中文摘要: |
| 摘要 目的：探讨卵巢癌组织中长链非编码核糖核酸（RNA）人类白细胞抗原复合体18（lncRNA HCG18）、微小RNA-152-3p（miR-152-3p）的表达情况与患者临床病理特征及预后的关系。方法：选择2016年1月至2021年1月我院收治的卵巢癌患者185例为研究对象。采用聚合酶链式反应（PCR）法检测并比较术中获取的卵巢癌组织与癌旁组织（距离癌组织边缘≥2 cm）lncRNA HCG18、miR-152-3p表达。分析lncRNA HCG18、miR-152-3p表达与卵巢癌患者临床病理特征之间的关系。对卵巢癌患者实施3年随访，采用Kaplan-Meier生存曲线比较lncRNA HCG18、miR-152-3p 高表达、低表达的卵巢癌患者3年累积生存率。采用Cox风险模型分析卵巢癌患者预后的影响因素。结果：lncRNA HCG18表达水平比较，卵巢癌组织高于癌旁组织（P＜0.05），miR-152-3p表达水平比较，卵巢癌组织低于癌旁组织（P＜0.05）。卵巢癌组织中lncRNA HCG18、miR-152-3p表达水平与国际妇产科联盟（FIGO）分期、分化程度、腹腔积液、淋巴结转移有关（P＜0.05）。高lncRNA HCG18组3年累积生存率为41.57%（37/89），低于低lncRNA HCG18组的70.65%（65/92），差异有统计学意义（P＜0.05）；高miR-152-3p组3年累积生存率75.53%（71/94），高于低miR-152-3p组的35.63%（31/87），差异有统计学意义（P＜0.05）。Cox比例风险模型分析结果显示，FIGO分期III~IV期、分化程度为高、中分化、腹腔积液、淋巴结转移、lncRNA HCG18升高，miR-152-3p降低是卵巢癌患者预后不良的危险因素。结论：卵巢癌组织中lncRNA HCG18高表达，miR-152-3p低表达与恶性临床病理特征及预后不良的发生有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression of long non-coding ribonucleic acids (lncRNA) human leukocyte antigen complex group 18 (lncRNA HCG18) and microRNA-152-3p (miR-152-3p) in ovarian cancer tissues and their relationship with clinicopathological features and prognosis of patients. Methods: 185 ovarian cancer patients admitted to our hospital from January 2016 to January 2021 were selected as the study subjects. The expression of lncRNA HCG18 and miR-152-3p in ovarian cancer tissues and adjacent tissues (≥ 2 cm from the edge of cancer tissues) were detected and compared by polymerase chain reaction (PCR). The relationship between the expression of lncRNA HCG18, miR-152-3p and the clinicopathological features of ovarian cancer patients was analyzed. Ovarian cancer patients were followed up for 3 years, the 3 years cumulative survival rate in ovarian cancer patients with high expression and low expression of lncRNA HCG18 and miR-152-3p were compared by Kaplan-Meier survival curve. The prognostic factors of ovarian cancer patients were analyzed by Cox risk model was used to analyze. Results: Comparison of the expression levels of lncRNA HCG18, ovarian cancer tissues was higher than that of adjacent tissues (P<0.05), and Comparison of the expression levels of miR-152-3p, ovarian cancer tissues was lower than that of adjacent tissues (P<0.05). The expression levels of lncRNA HCG18 and miR-152-3p in ovarian cancer tissues were related to International Federation of Gynecology and Obstetrics (FIGO) stage, degree of differentiation, ascites and lymph node metastasis (P<0.05). The 3 years cumulative survival rate in high lncRNA HCG18 group was 41.57% (37/89), which was lower than 70.65% (65/92) in low lncRNA HCG18 group, there was a difference of statistical significance (P<0.05). The 3 years cumulative survival rate in high miR-152-3p group was 75.53% (71/94), which was higher than 35.63% (31/87) in low miR-152-3p group, there was a difference of statistical significance (P<0.05). Cox proportional hazard model analysis showed that, FIGO stage III~IV, high and moderate differentiation, ascites, lymph node metastasis, lncRNA HCG18 increased, miR-152-3p decreased were risk factors for poor prognosis in ovarian cancer patients. Conclusion: The high expression of lncRNA HCG18 and the low expression of miR-152-3p in ovarian cancer tissues are relate to the occurrence of malignant clinicopathological features and poor prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
